| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/15/2003 | EP1274405A2 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 01/15/2003 | EP1274398A2 Effervescent granules and methods for their preparation |
| 01/15/2003 | EP1169317B1 Triarylimidazoles |
| 01/15/2003 | EP1063995B1 Combination for the treatment of alcohol dependence containing an opioid antagonist and a nmda receptor complex modulator |
| 01/15/2003 | EP0937057B1 Novel (-)-enantiomers of cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| 01/15/2003 | EP0851756B1 Use of ondansetron in the manufacture of a medicament for the treatment of tremor |
| 01/15/2003 | EP0820451B1 Novel heterocyclic compounds |
| 01/15/2003 | EP0787723B1 Cyclopropachromenecarboxylate derivatives |
| 01/15/2003 | EP0751769B1 Medical treatment using thyroid hormones |
| 01/15/2003 | EP0749981B1 Monoclonal antibody specific for pd-ecgf / thymidine phosphorylase |
| 01/15/2003 | EP0729468B1 Non-peptide tachykinin receptor antagonists |
| 01/15/2003 | EP0713483B1 Amidine derivatives with nitric oxide synthetase activities |
| 01/15/2003 | EP0659078B1 Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system |
| 01/15/2003 | EP0584347B1 Enantiomeric hydroxylated xanthine compounds |
| 01/15/2003 | CN1391605A Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 01/15/2003 | CN1391580A Peptides |
| 01/15/2003 | CN1391574A Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition |
| 01/15/2003 | CN1391573A Bicyclic imidazo-3-yl-amine derivatives |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391564A Chemical compounds |
| 01/15/2003 | CN1391556A IL-8 receptor antagonists |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391474A 5-membered heterocycle derivatives, production thereof and use as medicaments |
| 01/15/2003 | CN1391473A VLA-4 inhibitor compounds |
| 01/15/2003 | CN1391465A 包衣 Coating |
| 01/15/2003 | CN1391464A Formulation for menopausal women |
| 01/15/2003 | CN1390926A Wine containing sobering-up factor |
| 01/15/2003 | CN1390590A Health-care food for improving sleep |
| 01/15/2003 | CN1390586A Plaster fr treating facial paralysis |
| 01/15/2003 | CN1390577A Pill of tortoise plastron and turtle shell |
| 01/15/2003 | CN1390543A Oxiracetam injection |
| 01/15/2003 | CN1098843C Isoxazoles |
| 01/15/2003 | CN1098705C Oral medicine for diseases of cranial nerves system and preparing method thereof |
| 01/15/2003 | CN1098704C Preparation of hemiplegia treating capsule |
| 01/15/2003 | CN1098690C Microencapsulated bovine adrenal medulla chromaffincell medicine used for treating Parkinson's disease |
| 01/15/2003 | CN1098654C Kelp product and its production method and application |
| 01/14/2003 | US6506940 Process for converting stereoisomers of sertraline into sertraline |
| 01/14/2003 | US6506928 Derivative in which fullerene is linked to at least one dendron having at least one protic group which imparts water solubility |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506900 Epoxidation of the 2,2-dithienyl-2-hydroxyacetic acid ester; esterification |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506799 Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and |
| 01/14/2003 | US6506780 Benzophenones and sulfones as inhibitors of glycine uptake |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506775 Substituted benzylaminopiperidine compounds |
| 01/14/2003 | US6506774 The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506772 Pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are the adenosine receptor. |
| 01/14/2003 | US6506770 Antiviral compounds |
| 01/14/2003 | US6506768 Tetrahydro γ-carbolines |
| 01/14/2003 | US6506765 Apomorphine derivatives and methods for their use |
| 01/14/2003 | US6506762 Certain alkylene diamine-substituted heterocycles |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506753 Anxiolytic agents, anticonvulsants |
| 01/14/2003 | US6506750 Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/14/2003 | US6506748 Aromatic heterocyclic compounds as antiinflammatory agents |
| 01/14/2003 | US6506727 Contacting said nerve with purified platelet-derived growth factor and a second purified growth factor selected from the group consisting of insulin-like growth factor-I and acidic fibroblast growth factor |
| 01/14/2003 | US6506582 Extended by aspartic acid at 5' end and shortened at 3' end by one to eight amino acids; nonimmunogenic; binds CD4 lymphocytes |
| 01/14/2003 | US6506580 Splice variants for human 5-HT4 serotonin receptor and their applications, in particular for screening |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | US6506399 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 01/14/2003 | CA2249501C Method of preparing and using isoflavones |
| 01/14/2003 | CA2246758C Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii |
| 01/14/2003 | CA2114313C Bpc peptides, their preparation and use |
| 01/14/2003 | CA2067975C Buffered matrix aspirin tablet |
| 01/09/2003 | WO2003003010A1 Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson’s disease |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002742A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | WO2003002739A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002569A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 01/09/2003 | WO2003002568A1 Carbohydrate derivatives |
| 01/09/2003 | WO2003002566A1 Purine derivatives as a2b adenosine receptor antagonists |
| 01/09/2003 | WO2003002565A1 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002559A2 Piperidine compounds for use as orexin receptor antagonist |
| 01/09/2003 | WO2003002556A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002552A1 Novel indole derivatives |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002543A1 Pyrimidinoxyalkylpiperazines and their therapeutic use |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002510A1 Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
| 01/09/2003 | WO2003002175A2 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | WO2003002147A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002122A1 Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002116A1 Zonisamide use in headache |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |